Navigation Links
Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors
Date:5/28/2009

res monthly injections with very close patient monitoring," concluded Danse.

About Retinitis Pigmentosa (RP)

Retinitis Pigmentosa (RP) is an inherited disease that causes the retina's rod and cone photoreceptors to gradually degenerate leading to loss of vision and blindness. The symptoms of RP predominately appear in young adults and affect approximately 100,000 people in the United States and over 1 million people worldwide. At this time there is no known cure or effective treatment for RP.

About NT-501

Neurotech's lead product, NT-501, consists of encapsulated human cells genetically modified to secrete ciliary neurotrophic factor (CNTF). CNTF is a growth factor capable of rescuing dying photoreceptors and protecting them from degeneration. NT-501 is designed to continually deliver a therapeutic dose of CNTF into the back of the eye.

About Encapsulated Cell Technology

Neurotech's core technology platform is Encapsulated Cell Technology (ECT), a unique technology that allows for the long-term, sustained delivery of therapeutic factors to the back of the eye. ECT implants consist of cells that have been genetically modified to produce a specific therapeutic protein and are encapsulated in a semi-permeable hollow fiber membrane. The diffusive characteristics of the hollow fiber membrane are designed to promote long-term cell survival by allowing the influx of oxygen and nutrients while simultaneously preventing direct contact of the encapsulated cells with the cellular and molecular elements of the immune system. The cells continuously produce the therapeutic protein which diffuses out of the implant at the target site. ECT thereby enables the controlled, continuous delivery of therapeutic factors directly to the retina, bypassing the blood-retina barrier.

About Neurotech Pharmaceuticals, Inc.

Neurotec
'/>"/>

SOURCE Neurotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results
2. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
3. Martek to Announce Second Quarter 2009 Results
4. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
5. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
6. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
7. Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
8. China Biologic Products Announces Strong First Quarter 2009 Results
9. China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results
10. China Biologic Products Announces 2009 First Quarter Results Conference Call
11. PharmAthene Reports First Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... Albany Molecular Research Inc. (NASDAQ: AMRI ... AMRI,s President and Chief Executive Officer, will present at ... Conference on Wednesday, May 13, 2015 at 4:20 p.m. ... presentation can be accessed at AMRI,s Investor Relations web ... will be archived for 90 days following the live ...
(Date:4/30/2015)... 30, 2015   Tamir Biotechnology , a leading ... on its Ebola antiviral therapy program. ... is currently being evaluated and considered by a number ... Ebola. During the first quarter of 2015, the company ... Accelerate The Evaluation of Potential Treatments and Vaccines For ...
(Date:4/30/2015)... -- The following is an open letter sent April 30, ... Corp (NYSE: CO ) from Jayhawk Capital. ... of China Cord Blood Corp (" China Cord ") will ... from Golden Meditech Holdings Co Ltd ("Golden Med"). Certainly, a ... Golden Med and Mr. Kam, the Chairman of both ...
(Date:4/30/2015)... - Continued Advancement Toward ...   Shire (LSE: SHP, NASDAQ: SHPG ... March 31, 2015. Financial Highlights Q1 ... Total revenues $1,488 million +11% +15% Non GAAP operating ... from continuing operations $475 million +55% Non GAAP EBITDA ...
Breaking Biology Technology:AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 2April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 3April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 4April 30, 2015 Open Letter to the Board of China Cord Blood Corp from Jayhawk Capital 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 2Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 3Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 4Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 5Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 6Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 7Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 8Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 9Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 10Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 11Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 12Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 13Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 14Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 15Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 16Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 17Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 18Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 19Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 20Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 21Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 22Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 23Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 24Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 25Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 26Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 27Shire Delivers Strong Revenue Growth and Cash Generation; 20% Increase in Non GAAP Earnings per ADS 28
... accuracy: DNA vaccines that home in on DCs are ... develop new vaccines against infectious diseases is DNA vaccination. ... vaccine, the body converts the information in the DNA ... However, current DNA vaccines induce relatively weak immune responses ...
... UK, 6 March 2008 Elsevier, the world-leading ... and services, announced today Hybrid Materials 2009: The ... which will take place in Tours, France, 15-19 ... has experienced a 14% annual growth in published ...
... DNDN ) will release its fourth quarter financial results on,Thursday, March ... PT; 11:00 a.m. ET to review fiscal year 2007 financial results,and ... follows:, Time: 11:00 AM ... March 13, 2008 Dial-in: 1-877-548-7901 (domestic) or +1-719-325-4844 ...
Cached Biology Technology:JCI online early table of contents: March 6, 2008 2JCI online early table of contents: March 6, 2008 3JCI online early table of contents: March 6, 2008 4Hybrid materials: Exciting interdisciplinary field offering future solutions for industry 2-Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET- 2
(Date:4/8/2015)... N.C. , April 8, 2015  Infinisource, ... solutions and services, and Morpho, a leading supplier ... partnership to produce the market,s most advanced biometrically-enabled ... Infinisource,s iSolved NXG time clock is setting a ... and labor data for the small and mid-size ...
(Date:4/2/2015)... , April 2, 2015 ... DERMALOG by far outperforms the strongest competitors, showing ... high accuracy, the system is capable of a ... speed proves up to be ten times faster ... its runner-up performance.      (Photo: ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
Breaking Biology News(10 mins):iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2
... Des Moines, Iowa, USA March 18, 2008 A ... of Rwandan rain forest will have a greater range ... of Africas most ambitious forest restoration and ecological research efforts ... Park, said today that a 30-mile (50km) tree corridor will ...
... the United Kingdom and France have identified four ... of Creutzfeldt-Jakob disease. The study, published March 14th ... these subgroups could represent distinct prion strains in ... Prion diseases are transmissible neurodegenerative disorders characterized ...
... Take a deers body, attach a camels head and add ... odd-ball antelope with the enormous schnoz that lives on the isolated ... they are strange-looking due to over-hunting. Now, according to a ... as well. ...
Cached Biology News:Rwanda conservation effort to link isolated chimps to distant forest 2Rwanda conservation effort to link isolated chimps to distant forest 3Asia's odd-ball antelope faces migration crisis 2
... Luminometer has been designed,for the detection ... measurements of glow and flash luminescence ... light remain nearly constant,over a longer ... for very fast reactions,requiring at least ...
... than western blotting. Get results sooner and save ... gel detection. Eliminates the need for a membrane ... All reagents are ready-to-use. No reagents to prepare ... 2 reagents required. Guarantees a simple to perform, ...
... The EZ-Tn5™ Plasmid-Based Deletion Machine is ... vitro transposition system developed by Goryshin and ... generation of nested families of deletions and ... cloned in a transposon-containing plasmid vector. Although ...
... This kit is designed to knockout or alter ... less than one week. Red/ET recombination allows the ... precise, specific, and faithful manner. An FRT-flanked kanamycin ... which can be used to replace a gene ...
Biology Products: